Effect of fish oil on circulating asymmetric dimethylarginine and adiponectin in overweight or obese patients with atrial fibrillation

Elnaz Khorrami1 | Mohammad Javad Hosseinzadeh-Attar1,2,3 | Ahmad Esmaillzadeh4 | Elham Alipoor5 | Mostafa Hosseini6 | Zahra Emkanjou7 | Roya Kolahdouz Mohammadi5 | Sina Moradmand8

1Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
2Cardiac Primary Prevention Research Center (CPPRC), Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
3Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia
4Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
5Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
6Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
7Department of Cardiology, Shahid Rajaee Heart Center, Iran University of Medical Sciences, Tehran, Iran
8Department of Cardiology, Tehran University of Medical Sciences, Tehran, Iran

Correspondence
Mohammad Javad Hosseinzadeh-Attar, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, No144, Hojjatdoust St., Naderi St., Keshavarz Blvd., Tehran 14155-6117, Iran. Emails: hosseinzadeh.md.phd@gmail.com; mhosseinzadeh@tums.ac.ir

Funding information
Tehran University of Medical Sciences & Health Services, Grant/Award Number: 18479

Abstract
Obesity and adipose-derived peptides might be involved in the pathogenesis of atrial fibrillation (AF). Adiponectin plays a major role in the modulation of several metabolic pathways, and asymmetric dimethylarginine (ADMA) has been suggested to be predictive of AF and associated adverse events. The aim of this study was to investigate the effect of fish oil supplementation on circulating adiponectin and ADMA in overweight or obese patients with persistent AF. In this randomized, double-blind, placebo-controlled trial, 80 overweight or obese (body mass index (BMI) ≥ 25 kg/m²) patients with persistent AF were randomly assigned to two groups to receive either 2 g/day fish oil or placebo, for 8 weeks. Serum levels of adiponectin and ADMA, and anthropometric indexes were measured. This study showed that serum adiponectin concentrations increased significantly following fish oil supplementation compared with the placebo group (13.15 ± 7.33 vs. 11.88 ± 6.94 µg/ml; \( p = .026 \)). A significant reduction was also observed in serum ADMA levels in the fish oil compared with the placebo group following the intervention (0.6 ± 0.13 vs. 0.72 ± 0.15 µmol/L; \( p = .001 \)). The changes in serum adiponectin and ADMA concentrations remained significant after adjustments for baseline values, age, sex, and changes of BMI and waist circumference (\( p = .011 \) and \( p = .001 \), respectively). In conclusion, 8 weeks supplementation with fish oil increased serum adiponectin and decreased ADMA concentrations in overweight or obese patients with persistent AF. As adiponectin and ADMA are suggested to be involved in many pathways associated with AF, the current findings might be promising in the clinical management of this disease, an issue that needs further investigations.

KEYWORDS
adiponectin, asymmetric dimethylarginine, atrial fibrillation, fish oil, obesity
1 | INTRODUCTION

Atrial fibrillation (AF) is the most common form of arrhythmia, which could increase the risk of stroke and thromboembolic events (Go et al., 2001). It was estimated that 2.3 million people were affected by AF in the United States in 2001, which will increase to more than 5.6 million by the year 2050 (Go et al., 2001). Obesity is considered as an independent risk factor of short- and long-term incidence of AF. Each unit increase in body mass index (BMI) was associated with about 4% increased risk of AF (Tedrow et al., 2010; Wang et al., 2004). Obesity might contribute to AF through mechanisms such as inflammation and oxidative stress, insulin resistance, changes in metabolic by-products such as advanced glycation end products and related disturbances in myocardial metabolism, which are correlated with atrial structural and functional abnormalities (Abed & Wittert, 2013; Goudis, Korantzopoulos, Ntalas, Kallergis, & Ketikoglou, 2015). Endothelial dysfunction is another obesity-associated disorder that might contribute to AF (O’Neal et al., 2014).

Other factors such as hypertension and epicardial fat might also contribute to atrial electro-structural dysfunction (Abed & Wittert, 2013; Goudis et al., 2015). Epicardial fat has strong relationship with BMI and especially with visceral adipose tissue (Rabkin, 2014). Adipose tissue produces lots of bioactive molecules or adipocytokines, which are involved in different physiological and pathophysiological pathways. Adiponectin is a major adipokine with well-known insulin-sensitizing, anti-inflammatory, antiproliferative, and anti-atherogenic properties (Ouchi, Parker, Lugus, & Walsh, 2011). Lower release of epicardial adiponectin was associated with development of AF after cardiac surgery (Kourliouros et al., 2011). Circulating adiponectin was significantly lower in AF compared to controls with normal sinus rhythm (Choi et al., 2012), and was inversely associated with major cardiovascular events in women with AF (Hernández-Romero et al., 2013). Asymmetric dimethylarginine (ADMA), a major inhibitor of nitric oxide (NO) synthase, is another peptide secreted by adipocytes (Spoto, Parlongo, Parlongo, Sgro, & Zoccali, 2007), which can induce endothelial dysfunction, inflammation, and oxidative stress in cardiovascular disorders (Bouras et al., 2013). ADMA levels were significantly higher in AF compared to non-AF individuals candidate for coronary angiography (Chao et al., 2013) and healthy controls (Cengel et al., 2008). Higher ADMA levels were associated with increased risk of AF recurrence following electrical cardioversion (Xia et al., 2008) and catheter ablation (Yang et al., 2011). It has been suggested that ADMA could have prognostic value in predicting AF in high-risk patients (Stamboul et al., 2015). Besides, studies have indicated the predictive value of ADMA in determining the adverse events such as mortality and stroke in AF (Chao et al., 2013; Horowitz et al., 2018).

Little is known about the effects of nutritional supplements on circulating levels of these biomarkers in patients with AF. Higher serum levels of long-chain omega-3 fatty acids have been linked with a lower incidence of AF (Virtanen, Mursu, Voutilainen, & Tuomainen, 2009). Moreover, fish oil supplementation led to lower incidence of AF (Calò et al., 2005), duration of AF and ICU stay (Farahani et al., 2017) after coronary artery bypass graft surgery (CABG).

However, studies investigating the effect of fish oil supplementation on these mediating factors are scarce in patients with AF. Thus, the aim of the current study was to examine the effect of fish oil supplementation on serum ADMA and adiponectin concentrations in overweight or obese patients with persistent AF.

2 | MATERIALS AND METHODS

2.1 | Study population

In the current randomized, double-blind, placebo-controlled, parallel design trial, 80 overweight or obese (25 ≤ BMI ≤ 40 kg/m²) patients with persistent AF, age ≥ 50 years, and on warfarin therapy were enrolled.

Patients with thyroid dysfunction, valvular heart disease, heart failure, and CABG in the past 3 months were not included. Besides, smokers, patients with a history of drug or alcohol abuse, those with recent acute illnesses and infectious diseases, woman with hormone replacement therapy, participants consuming fish oil derivatives in the past 3 months, or allergic to fish oil were not included in this study. Patients were excluded if they need CABG or did not consume more than 10% of capsules. The sample size was calculated, considering adiponectin as the main variable, based on the formula for randomized clinical trials, with type I (a) error of 0.05 and type II error (b) of 0.20 (power = 80%). The calculation showed that 38 participants in each group would be sufficient. Assuming a drop-out of 10%, the final sample size was determined to be 42 patients in each group. Ethical Committee of Tehran University of Medical Sciences approved the study protocol, and informed written consent was obtained from all patients. This clinical trial was registered with a national registry system of clinical trials (Registration ID at irct.ir: IRCT2012110411362N1).

2.2 | Study design

Patients were assigned to two groups using random stratified permuted blocks. Two diabetes categories (yes/no) were considered as strata to eliminate the confounding effect of this disease. Patients were randomly assigned to two groups to receive either 2 g/day (two 1,000-mg capsules) fish oil (each capsule contained 300 mg eicosapentaenoic acid (EPA) and 200 mg docosahexaenoic acid (DHA)) or 2 g/day olive oil as placebo for 8 weeks. Fish oil supplements and placebo were produced by Daana Company. The placebo and fish oil capsules were the same in size, weight, and color.

Patients were followed up by phone weekly. To assess compliance, we asked the participants to bring back the empty box of the capsules at the end of the study. All patients were requested not to change their usual physical activity and dietary intakes throughout the study period and not to consume any additional supplement. A
3-day 24-hr dietary recall (two weekdays and one weekend) was completed to examine reported dietary intakes at baseline and following the intervention. Mean dietary intakes were analyzed using Nutritionist IV software (N Squared Computing) modified for some local foods.

2.3 | Assessment of variables

Anthropometric indices including height and weight were measured using Seca scale and tape (Germany) before and after the intervention, with light clothing and no shoes. BMI was calculated as weight in kilograms divided by height in meters squared. Waist circumference was measured between the lowest rib and the iliac crest, using a nonelastic tape. An overnight 10-ml fasting venous blood sample was taken at baseline and at the end of the trial. Samples were centrifuged at 3,000 rpm for 15 min to separate serum and stored at −80°C until the analysis. Commercial enzyme-linked immunosorbent assay (ELISA) kits were used to quantify serum levels of adiponectin (Mediagnost) and ADMA (DLD). Intra- and interassay coefficients of variation were <10% for these measurements.

2.4 | Statistical methods

Normal distribution of the variables was assessed using the Kolmogorov–Smirnov test. Independent samples t test or Mann–Whitney U test was applied to compare variables between the two groups at baseline. Chi-square test was used to compare categorical variables between the two groups. To examine the effect of supplementation on main variables, we applied analysis of covariance (ANCOVA) adjusting for baseline measurements as well as, age, sex, and changes in BMI and waist circumference. p values were considered significant at the level of <.05. Statistical analysis was performed using SPSS software (IBM SPSS Statistics for Windows, Version 18).

3 | RESULTS

3.1 | General characteristics

Four patients did not finish the study: two in the fish oil group due to personal reasons and two in the control group due to consuming <10% of the capsules (n = 1) and death (n = 1) (Figure 1). No adverse effects were reported by patients after taking supplements or placebos.

General baseline characteristics of the study participants are shown in Table 1. No significant differences were observed in mean age, BMI, and waist circumference between the fish oil and placebo groups at baseline. Moreover, the prevalence of diabetes, hypertension, and hypercholesterolemia was not different between the two groups. Reported dietary intakes of energy, macronutrients, EPA, DHA, and α-linolenic acid (ALA) were not significantly different between the two groups at baseline (Table 1). Besides, there were no considerable differences in reported dietary intakes at the end of the study.

3.2 | ADMA and adiponectin

Serum adiponectin concentrations increased significantly following fish oil supplementation compared with the control group (13.15 ± 7.33 vs. 11.88 ± 6.94 μg/ml, p = .026). Furthermore, a significant reduction was observed in serum ADMA levels in the fish oil compared with the control group following the intervention (0.6 ± 0.13 vs. 0.72 ± 0.15 μmol/L, p = .001). Changes in serum adiponectin and ADMA remained significant after adjustment for baseline values, age, sex, changes of BMI and waist circumference (p = .011 and p = .001, respectively) (Table 2).

3.3 | Anthropometric changes

Weight (0.99 ± 1.97 vs. 0.06 ± 1.74 kg, p = .029), BMI (0.40 ± 0.84 vs. 0.03 ± 0.7 kg/m², p = .029), and waist circumference (2.42 ± 2.15 vs. 0.1 ± 1.34 cm, p < .001) were significantly decreased in the fish oil compared to the control group (Table 3).

4 | DISCUSSION

In this randomized, placebo-controlled, parallel design clinical trial, 2 g/daily fish oil supplementation for 8 weeks had a significant effect on increasing adiponectin and decreasing ADMA serum concentrations.

The effect of n-3 polyunsaturated fatty acids on increasing circulating adiponectin has been well recognized in experimental and clinical models (Flachs et al., 2006; Itoh et al., 2007). However, little is known about the effect of these fatty acids on adiponectin in AF. EPA treatment (300 mg/kg daily for 4 weeks) in a rabbit model declined the increased duration of AF and atrial fibrosis associated with heart failure. This change was accompanied with increased adiponectin and decreased tumor necrosis factor alpha (TNF-α) expression in the atrium and epicardial adipose tissue (Kitamura et al., 2011). A clinical study showed neither a difference in the incidence of postcardiac surgery AF nor a change in adiponectin concentration compared to controls following 900 mg daily consumption of EPA for 3–6 months (Yamamoto et al., 2014).

Left ventricular (LV) hypertrophy is a risk factor for AF development (Healey & Connolly, 2003). In an animal study of LV hypertrophy, adiponectin levels increased significantly in both normal low-fat and high-fat diets supplemented with fish oil (2.3% of energy intake as EPA + DHA). Besides, a normal low-fat diet supplemented with EPA + DHA prevented LV hypertrophy (Shah et al., 2009). Another experimental study showed that fish oil-enriched diet (5%)
prevented LV hypertrophy, increased serum adiponectin concentration, and suppressed inflammatory markers compared to corn oil diet (5%) (Halade, Williams, Lindsey, & Fernandes, 2011). A large population-based study showed that low adiponectin levels could be associated with higher marker of LV hypertrophy (Pääkkö, Ukkola, Ikäheimo, & Kesäniemi, 2010).

Adiponectin has been proposed as a marker of peroxisome proliferator-activated receptor-gamma (PPAR-γ) activity (Wagner et al., 2009) and also a mediator of multiple effects of PPAR-γ (Bouskila, Pajvani, & Scherer, 2005) and PPAR-α (Tsuchida et al., 2005). PPAR-γ mRNA was decreased significantly in AF compared to non-AF individuals, and also in persistent AF compared to the paroxysmal type (Chen et al., 2009). PPAR-γ agonists, such as pioglitazone, reduce atrial remodeling and AF duration significantly, potentially through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms (Liu, Liao, Yang, & Tang, 2016; Xu et al., 2012). Omega-3 fatty acids are natural agonists of PPAR-γ and PPAR-α (Grygiel-Górniak, 2014). Adiponectin could also inhibit angiotensin II-induced cardiac inflammation and fibrosis by increasing macrophage autophagy and up-regulation of anti-inflammatory mediators (Fujita et al., 2008; Qi,
Jia, Li, Li, & Du, 2014). Low circulatory levels of adiponectin contribute to insulin resistance and endothelial vascular dysfunction (Goldstein & Scalia, 2004), which could be involved in AF pathogenesis (Abed & Wittert, 2013; Goudis et al., 2015; O’Neal et al., 2014).

Accordingly, these studies suggest that despite some observational studies indicating a direct relationship between adiponectin and higher risk of AF in a population-based cohort (Macheret et al., 2015) and after catheter ablation in patients with paroxysmal AF (Kim et al., 2017), this peptide may modulate pathophysiological pathways in AF. Higher adiponectin levels in those studies might play a compensatory role to control AF.

In the current study, ADMA serum concentration decreased in patients with persistent AF following 2 g/day fish oil supplementation for 8 weeks.

It has been reported that serum ADMA levels decreased following 1,800 mg daily EPA treatment in patients in chronic phase

| TABLE 2 | Changes in adiponectin and ADMA concentrations in patients with AF before and following 8-week supplementation with fish oil |
|---------|---------------------------------------------------------------|
|          | Control (n = 40) | Fish oil (n = 40) | 95% CI | p |
| Adiponectin (µg/ml) | Mean ± SD | Mean ± SD | Diff | Lower | Upper | p |
| Before | 12.38 ± 7 | 12.34 ± 6.8 | 0.04 | -3.032 | 3.111 | .979* |
| After | 11.88 ± 6.94 | 13.15 ± 7.33 | -1.309 | -2.453 | -0.164 | .026** |
| Change | 0.51 ± 2.37 | -0.8 ± 2.74 | 1.31 | 0.168 | 2.452 | .025* |
| ADMA (µmol/L) | Mean ± SD | Mean ± SD | Diff | Lower | Upper | p |
| Before | 0.69 ± 0.13 | 0.64 ± 0.13 | 0.049 | -0.008 | 0.106 | .088* |
| After | 0.72 ± 0.15 | 0.6 ± 0.13 | 0.104 | 0.043 | 0.164 | .001** |
| Change | -0.03 ± 0.17 | 0.05 ± 0.14 | -0.072 | -0.142 | -0.004 | .04* |

Note: p values in the rows refer to pre- to post-differences within the each study group.
*Based on independent samples t test.
**Adjusted for baseline values based on ANCOVA.
***Based on paired samples test.

| TABLE 3 | Changes in anthropometric indexes in patients with AF before and following 8-week supplementation with fish oil |
|---------|---------------------------------------------------------------|
|          | Control (n = 40) | Fish oil (n = 40) | 95% CI | p |
| Weight (kg) | Mean ± SD | Mean ± SD | Diff | Lower | Upper | p |
| Before | 73.8 ± 12.9 | 73.6 ± 13.3 | 0.23 | -5.604 | 6.064 | .938* |
| After | 73.7 ± 13 | 72.6 ± 13.3 | 0.927 | 0.095 | 1.758 | .029** |
| Change | 0.06 ± 1.74 | 0.99 ± 1.97 | -0.925 | -1.751 | -0.099 | .029* |
| Body mass index (kg/m²) | Mean ± SD | Mean ± SD | Diff | Lower | Upper | p |
| Before | 29.2 ± 4.2 | 29 ± 4.9 | 0.164 | -1.887 | 2.215 | .874* |
| After | 29.2 ± 4.3 | 28.6 ± 4.8 | 0.382 | 0.04 | 0.725 | .029** |
| Change | 0.03 ± 0.7 | 0.4 ± 0.84 | -0.378 | -0.722 | -0.034 | .032* |
| Waist circumference (cm) | Mean ± SD | Mean ± SD | Diff | Lower | Upper | p |
| Before | 100.3 ± 8.9 | 102.3 ± 16 | -1.963 | -7.715 | 3.79 | .499* |
| After | 100.2 ± 8.8 | 99.9 ± 16.2 | 2.321 | 1.517 | 3.126 | <.001** |
| Change | 0.1 ± 1.34 | 2.42 ± 2.15 | -2.32 | -3.119 | -1.521 | <.001* |
| p*** | 0.640 | <0.001 |

Note: p values in the rows refer to pre- to post-differences within the each study group.
*Based on independent samples on t test.
**Adjusted for the baseline values based on ANCOVA.
***Based on paired samples test.
of cerebral infarction (Hagiwara, Nishiyama, & Katayama, 2011). However, 1-month supplementation with 1 g/day n-3 PUFAs in patients with acute myocardial infarction (Haberkat et al., 2011) or 2.4 g/day n-3 PUFAs for 36 months in men with hypercholesterolemia (Eid et al., 2006) did not affect ADMA levels.

However, these studies had different designs and pathophysiological backgrounds and little is known about the effect of n-3 fatty acids on ADMA concentration in AF.

Asymmetric dimethylarginine has been proposed to have prognostic value in determining AF in high-risk patients (Stamboul et al., 2015) and the adverse events such as mortality and stroke in AF (Chao et al., 2013; Horowitz et al., 2018). Treatment with 10 mg daily rosvastatin for 3 months following elective electrical cardioversion decreased recurrence of AF through reduction of ADMA levels (Xia, Yin, Li, Song, & Qu, 2009). ADMA might be involved in atrial remodeling. Higher ADMA levels were correlated with high incidence of non-pulmonary veins ectopies, which were predictive of AF (Yang et al., 2011). Increased ADMA concentration in AF could be associated with NO deficiency, which in turn leads to cardiomyocyte apoptosis (Feng et al., 2002). ADMA has been suggested as a link between AF with oxidative stress and inflammation, endothelial dysfunction, and atherosclerosis (Chao et al., 2013). Inflammation is involved in AF pathogenesis (Abed & Wittert, 2013; Goudis et al., 2015). ADMA is considered a determinant and biochemical measure of endothelial dysfunction (Paiva et al., 2010), which might also contribute to AF (O’Neal et al., 2014).

Adiponectin and ADMA are adipose-derived factors. Thus, it might be speculated that their changes in this study originated from decrease in anthropometric indexes not fish oil supplementation. However, it should be considered that changes in weight and BMI, although statistically significant, are negligible and clinically irrelevant. The potential effect of BMI and waist circumference changes on adiponectin and ADMA was also considered in statistical analysis. Additionally, considering the BMI cutoff of more than 25 kg/m² confined the effect of weight status on adipokines’ changes and was a strength of this study as many patients with AF are overweight or obese.

Some limitations are needed to be mentioned for this trial. Our study provided observations on changes of adiponectin and ADMA serum concentrations following fish oil supplementation in patients with persistent AF, but did not directly evaluate clinical outcomes and mechanisms associated with adiponectin and ADMA. However, considering the important and close relationship of these factors with mechanisms involved in AF pathogenesis and the predictive and prognostic role of ADMA in AF, the corresponding changes following fish oil supplementation are considerable and should be investigated with more details in future studies.

5 CONCLUSION

Eight weeks of fish oil supplementation led to increase in serum adiponectin and decrease in serum ADMA concentrations in patients with persistent AF.

ACKNOWLEDGMENTS

This study was supported by Tehran University of Medical Sciences & Health Services Grant 18479. The authors thank Dr Soraya Shahrzad for her overall support, Dr Kambiz Mozaffari and Mohammad Sepasi (Laboratory, Shahid Rajaee Heart Center) for their technical assistance and Dr Mehdi Yaseri for statistical consultation.

CONFLICT OF INTEREST

The authors declare that they do not have any conflict of interest.

ETHICAL APPROVAL

This study was approved by the Institutional Review Board of Tehran University of Medical Sciences.

INFORMED CONSENT

Written informed consent was obtained from all study participants.

ORCID

Mohammad Javad Hosseinzadeh-Attar https://orcid.org/0000-0002-5787-4089

Ahmad Esmaillzadeh https://orcid.org/0000-0002-8735-6047

Elham Alipoor https://orcid.org/0000-0002-9463-6354

REFERENCES

Abed, H. S., & Wittert, G. A. (2013). Obesity and atrial fibrillation. Obesity Reviews, 14, 929–938. https://doi.org/10.1111/obr.12056

Bouras, G., Deftereos, S., Tousoulis, D., Giannopoulos, G., Chatzis, G., Tsounis, D., ... Stefanadis, C. (2013). Asymmetric Dimethylarginine (ADMA): A promising biomarker for cardiovascular disease? Current Topics in Medicinal Chemistry, 13, 180–200.

Bouskila, M., Pajvani, U. B., & Scherer, P. E. (2005). Adiponectin: A relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? International Journal of Obesity (London), 29(Suppl. 1), S17–S23. https://doi.org/10.1038/sj.ijo.0802908

Calò, L., Bianconi, L., Colivicchi, F., Lamberti, F., Loricchio, M. L., de Ruvo, E., ... Santini, M. (2005). N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: A randomized, controlled trial. Journal of the American College of Cardiology, 45, 1723–1728.

Cengel, A., Sahinarslan, A., Biberoglu, G., Hasanoglu, A., Tavil, Y., Tulmac, M., & Ozdemir, M. (2008). Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiologica, 63, 33–37. https://doi.org/10.2143/ac.63.1.205329

Chao, T.-F., Lu, T.-M., Lin, Y.-J., Tsao, H.-M., Chang, S.-L., Lo, L.-W., ... Chen, S.-A. (2013). Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS ONE, 8, e71675. https://doi.org/10.1371/journal.pone.0071675

Chen, X., Bing, Z., He, J., Jiang, L., Luo, X., Su, Y., ... Wei, Y. (2009). Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation. Clinical Cardiology, 32, 337–345. https://doi.org/10.1002/clc.20566

Choi, B. J., Heo, J. H., Choi, I.-S., Lee, S.-W., Kim, H.-S., Lee, J. W., & Cha, T.-J. (2012). Hypoadiponectinemia in patients with paroxysmal atrial fibrillation. Korean Circulation Journal, 42, 668–673.

Eid, H. M., Arnesen, H., Hjerkinn, E. M., Lyberg, T., Ellingsen, I., & Seljeflot, I. (2006). Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. Nutrition and Metabolism, 3, 4.

Farahani, A. V., Azar, A. Y., Goodarzynnejad, H. R., Khorrami, E., Hosseinzadeh-Attar, M. J., Oshnouei, S., ... Ghourban Pour, F. (2017).
Fish oil supplementation for primary prevention of atrial fibrillation after coronary artery bypass graft surgery: A randomized clinical trial. *International Journal of Surgery*, 42, 41–48.

Feng, Q., Song, W., Lu, X., Hamilton, J. A., Lei, M., Peng, T., & Yee, S. P. (2002). Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. *Circulation*, 106, 873–879.

Flachs, P., Mohamed-Ali, V., Horakova, O., Rossmeisl, M., Hosseinzadeh-Attar, M. J., Hensler, M., ... Kopecky, J. (2006). Polysaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. *Diabetologia*, 49, 394–397. https://doi.org/10.1007/s00125-005-0053-y

Fujita, K., Maeda, N., Sonoda, M., Ohashi, K., Hibuse, T., Nishizawa, H., ... Funahashi, T. (2008). Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-α. *Atherosclerosis, Thrombosis, and Vascular Biology*, 28, 863–870.

Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001). Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*, 285, 2370–2375.

Goldstein, B. J., & Scalia, R. (2004). Adiponectin: A novel adipokine linking adipocytes and vascular function. *The Journal of Clinical Endocrinology & Metabolism*, 89, 2563–2568.

Goudis, C. A., Korantzopoulos, P., Ntalas, I. V., Kallergis, E. M., & Ketikoglou, D. G. (2015). Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links. *Journal of Cardiology*, 66, 361–369. https://doi.org/10.1016/j.jjc.2015.04.002

Grygiel-Górniak, B. (2014). Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications – A review. *Nutrition Journal*, 13, 17.

Haberk, M., Mizia - Stec, K., Mizia, M., Janowska, J., Gieszczyk, K., Chmiel, A., ... Gaśior, Z. (2011). N-3 polysaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction. *Clinical Nutrition*, 30, 79–85.

Hagiwara, H., Nishiyama, Y., & Katayama, Y. (2011). Effects of eicosapentaenoic acid on asymmetric dimethylarginine in patients in the chronic phase of cerebral infarction: A preliminary study. *Journal of Stroke and Cerebrovascular Diseases*, 20, 474–478.

Halade, G. V., Williams, P. J., Lindsey, M. L., & Fernandes, G. (2011). Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. *Pharmacological Research*, 63, 300–307.

Healey, J. S., & Connolly, S. J. (2003). Atrial fibrillation: Hypertension as a causative agent, risk factor for complications, and potential therapy, but not through NO inhibitors in patients with acute myocardial infarction. *European Journal of Cardio-Thoracic Surgery*, 29, 228–232.

Hirata, K., Shiota, R., Sugiyama, Y., Kikuchi, Y., ... Kikuchi, Y. (2015). High circulating adiponectin level is associated with poor clinical outcome after catheter ablation for paroxysmal atrial fibrillation. *European Heart Journal*, 36, 1734–1741. https://doi.org/10.1093/eurheartj/ehv962

Kitamura, K., Shibata, R., Tsuji, Y., Shimano, M., Inden, Y., & Murohara, T. (2011). Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model. *American Journal of Physiology-Heart and Circulatory Physiology*, 300, H1814–H1821.

Kourilouros, A., Karastergiou, K., Nowell, J., Gukop, P., Tavakolli Hosseini, M., Valencia, O., ... Jahangir, M. (2011). Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery. *European Journal of Cardio-Thoracic Surgery*, 40, 605–611. https://doi.org/10.1093/eurheartj/ehq372

Li, H.-J., Liao, H.-H., Yang, Z., & Tang, Q.-Z. (2016). Peroxisome proliferator-activated receptor-γ is critical to cardiac fibrosis. *PPAR Research*, 2016. https://doi.org/10.1155/2016/2198645

Machere, F., Bartz, T. M., Dousset, L., Ix, J. H., Mukamal, K. J., Ziemann, S. J., ... Kizer, J. R. (2015). Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. *Heart*, 101, 1368–1374. https://doi.org/10.1136/heartjnl-2014-307015

O’Neal, W. T., Efrid, J. T., Yeboah, J., Nazarian, S., Alonso, A., Heckbert, S. R., & Soliman, E. Z. (2014). Brachial flow-mediated dilation and incident atrial fibrillation: The multi-ethnic study of atherosclerosis. *Atherosclerosis, Thrombosis, and Vascular Biology*, 34, 2717–2720. https://doi.org/10.1161/atvba ha.114.304560

Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation and metabolic disease. *Nature Reviews Immunology*, 11, 85–97. https://doi.org/10.1038/nri2921

Pääkkö, T., Ukkola, O., Iläheimö, M., & Kesäniemi, Y. A. (2010). Plasma adiponectin levels are associated with left ventricular hypertrophy in a random sample of middle-aged subjects. *Annals of Medicine*, 42, 143–149.

Päiviä, H., Kähönen, M., Lehtimäki, T., Alfthan, G., Viikari, J., Laaksonen, R., ... Juonala, M. (2010). Levels of asymmetrical dimethylarginine are predictive of brachial artery flow-mediated dilation 6 years later. The Cardiovascular Risk in Young Finns Study. *Atherosclerosis*, 212, 512–515. https://doi.org/10.1016/j.atherosclerosis.2010.06.041

Qi, G. M., Jia, L. X., Li, Y. L., Li, H. H., & Du, J. (2014). Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. *Endocrinology*, 155, 2254–2265. https://doi.org/10.1210/en.2013-2011

Rakbin, S. W. (2014). The relationship between epicardial fat and indices of obesity and the metabolic syndrome: A systematic review and meta-analysis. *Metabolic Syndrome and Related Disorders*, 12, 31–42. https://doi.org/10.1089/met.2013.0107

Shah, K. B., Duda, M. K., O’Shea, K. M., Sparagna, G. C., Chess, D. J., Khairallah, R. J., ... Stanley, W. C. (2009). The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: Role of cardiac phospholipid remodeling. *Hypertension*, 54, 605–611. https://doi.org/10.1161/hypertensionaha.109.135806

Spoto, B., Parlongo, R. M., Parlongo, G., Sgro, E., & Zoccali, C. (2007). The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. *Journal of Nephrology*, 20, 554–559.

Stamboul, K., Lorin, J., Lorgis, L., Guenancia, C., Beer, J.-C., Touzery, C., ... Zoccali, C. (2007). The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. *Journal of Nephrology*, 20, 554–559.

Takeda, S. I., Hori, K., Kato, M., Maeda, H., Yoko, H., ... Kurokawa, M. (2006). Fish oil reduces inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. *Pharmacological Research*, 56, 300–307.

Takeda, T., Orito, K., Usui, M., Tanaka, S., ... Kurokawa, M. (2005). Adiponectin links endothelial function and oxidative stress in patients with acute myocardial infarction. *Circulation*, 111, 1287–1294. https://doi.org/10.1161/circulationaha.104.452063

Tedesco, U. B., Conen, D., Ridker, P. M., Cook, N. R., Koplan, B., A., Manson, J. A. E., ... Albert, C. M. (2010). The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women’s health study). *Journal of the American College of Cardiology*, 55, 2319–2327. https://doi.org/10.1016/j.jacc.2010.02.029

Tsuchida, A., Yamauchi, T., Takekawa, S., Hada, Y., Ito, Y., Maki, T., & Kadowaki, T. (2005). Peroxisome proliferator-activated receptor (PPARα) activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: Comparison of activation of PPARα, PPARγ, and their combination. *Diabetes*, 54, 3358–3370.
Virtanen, J. K., Mursu, J., Voutilainen, S., & Tuomainen, T.-P. (2009). Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. *Circulation, 120*, 2315–2321.

Wagner, J. A., Wright, E. C., Ennis, M. M., Prince, M., Kochan, J., Nunez, D. J. R., ... Vassileva, M. T. (2009). Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. *Clinical Pharmacology and Therapeutics, 86*, 619–625.

Wang, T. J., Parise, H., Levy, D., D'Agostino, R. B. Sr, Wolf, P. A., Vasan, R. S., & Benjamin, E. J. (2004). Obesity and the risk of new-onset atrial fibrillation. *JAMA: The Journal of the American Medical Association, 292*, 2471–2477.

Xia, W., Qu, X., Yu, Y., Zhang, X., Feng, W., & Song, Y. (2008). Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. *Pacing and Clinical Electrophysiology, 31*, 1036–1040.

Xia, W., Yin, Z., Li, J., Song, Y., & Qu, X. (2009). Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. *Pacing and Clinical Electrophysiology, 32*, 1562-1566. https://doi.org/10.1111/j.1540-8159.2009.02554.x

Xu, D., Murakoshi, N., Igarashi, M., Hirayama, A., Ito, Y., Seo, Y., ... Aonuma, K. (2012). PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. *Journal of Cardiovascular Electrophysiology, 23*, 209–217. https://doi.org/10.1111/j.1540-8167.2011.02186.x

Yamamoto, T., Kajikawa, Y., Otani, S., Yamada, Y., Takemoto, S., Hirota, M., ... Fujiwara, T. (2014). Protective effect of eicosapentaenoic acid on insulin resistance in hyperlipidemic patients and on the postoperative course of cardiac surgery patients: The possible involvement of adiponectin. *Acta Medica Okayama, 68*, 349–361. https://doi.org/10.18926/amo/53024

Yang, L. I., Xiufen, Q. U., Shuqin, S., Yang, Y. U., Ying, S., Yanwei, Y. U., ... Dechun, Y. (2011). Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrhythmias after catheter ablation in patients with persistent atrial fibrillation. *Journal of Interventional Cardiac Electrophysiology, 32*, 147–154. https://doi.org/10.1007/s10840-011-9588-7

How to cite this article: Khorrami E, Hosseinzadeh-Attar MJ, Esmailzadeh A, et al. Effect of fish oil on circulating asymmetric dimethylarginine and adiponectin in overweight or obese patients with atrial fibrillation. *Food Sci Nutr.* 2020;8:2165–2172. https://doi.org/10.1002/fsn3.1518